Treatment with 212Pb-1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (TCMC)-NNV003 (anti-CD37) demonstrated efficacy and safety in preclinical models of CD37-expressing chronic lymphocytic leukemia and NHL [46]. Here, CD37 is linked to B-cell chronic lymphocytic leukemia.